Printer Friendly

INTERNATIONAL MUREX REPORTS NOTIFICATION OF 13-D FILING

 INTERNATIONAL MUREX REPORTS NOTIFICATION OF 13-D FILING
 TORONTO, Ontario, Nov. 13 /PRNewswire/ -- International Murex


Technologies Corporation (AMEX: MXX; TSE) has been informed that its major shareholder, Edward J. DeBartolo Jr., has transferred 2,055,990 shares of IMTC stock to Edward J. DeBartolo Sr.
 This transfer is for internal accounting reasons associated with business interests between them.
 All of the DeBartolo controlled shares continue to be subject to SEC Rule 144, which limits the shareholder's ability to sell shares in the open market.
 Toronto-based IMTC is an international medical diagnostic systems company dedicated to the development, manufacture and global marketing of cost-effective diagnostic tests for infectious diseases and products for the blood banking industry.
 -0- 11/13/91
 /CONTACT: C. Robert Cusick, president and chief executive officer of International Murex, 800-688-1332, or 416-408-4682/
 (MXX) CO: International Murex Technologies Corporation ST: Georgia, Ontario IN: MTC SU: BR-BN -- AT014 -- 4010 11/13/91 14:00 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 13, 1991
Words:154
Previous Article:SEARS DECLARES DIVIDEND ON OUTSTANDING PREFERRED SHARES
Next Article:RODE TO RESIGN AS PRESIDENT OF AMERITRUST CORP. ON MERGER COMPLETION
Topics:


Related Articles
INTERNATIONAL MUREX TECHNOLOGIES ANNOUNCES EQUITY OFFERING
INTERNATIONAL MUREX TECHNOLOGIES CORPORATION ANNOUNCES THIRD QUARTER RESULTS
INTERNATIONAL MUREX TECHNOLOGIES ANNOUNCES DOMINION BIOLOGICALS RECEIVES FDA NOTIFICATION OF FINAL SITE INSPECTION FOR NOVACLONE(TM) PRODUCTS
INTERNATIONAL MUREX TECHNOLOGIES CORPORATION ANNOUNCES EXERCISE OF OPTION AND INCLUSION IN TSE 300 COMPOSITE INDEX
INTERNATIONAL MUREX TECHNOLOGIES CORPORATION CLOSES EURO-EQUITY OPTION FOR NEW COMMON SHARES
INTERNATIONAL MUREX TECHNOLOGIES CORPORATION ANNOUNCES COMPLETION OF THE PURCHASE OF WELLCOME DIAGNOSTICS
BRITISH COURT RULES ON HEPATITIS C PATENT; MUREX CONTINUES TO SELL ANTI-HCV PRODUCTS
INTERNATIONAL MUREX PROMOTES J. DAVID THOLEN TO CHIEF EXECUTIVE OFFICER
INTERNATIONAL MUREX LICENSES TECHNOLOGY TO ABBOTT LABORATORIES
International Murex Reports First Quarter Earnings of $0.10 Per Share

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters